We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App





New Line of Immunoassay Stabilizers Launched at AACC Annual Meeting

By LabMedica International staff writers
Posted on 01 Aug 2016
The launch and immediate availability of a new line of advanced immunoassay stabilizers were announced prior to the commencement of the 2016 AACC Annual Meeting & Clinical Lab Expo (Philadelphia, PA, USA).

The Surmodics (Eden Prairie, MN, USA) StabilBlock Immunoassay Stabilizer, which will be on display in Booth 4047 of the expo, is advertised as the best available reagent for reducing non-specific binding to boost immunoassay signal-to-noise ratios.

Surmodics offers a family of immunoassay stabilizers, which preserve the conformation and activity of dried proteins on a wide range of surfaces, keeping antibodies and antigens at peak performance for long durations. More...
At the same time, the blocking mechanisms in these reagents reduce non-specific binding of interfering proteins to maximize assay sensitivity. With StabilCoat, StabilGuard, and the new StabilBlock immunoassay stabilizers, the company now offers three options to assay developers with a combination of blocking efficacy and long-term dried stability that is unmatched in the industry.

“As part of our commitment to being the premier provider of IVD assay components to improve performance and manufacturability of immunoassays, we continue to advance our offerings to meet the needs of our customers,” said Joe Stich, vice- president and general manager of Surmodics IVD. “We recognize that each assay has its own blocking requirements and our expanded portfolio of Immunoassay Stabilizers will enable assay developers to achieve the best results for each application.”

Related Links:
AACC Annual Meeting & Clinical Lab Expo
Surmodics




Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Automatic Hematology Analyzer
LABAS F9000
New
Staining System
RAL DIFF-QUIK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.